Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WIL Research Acquires Midwest BioResearch | Contract Pharma

What are you searching for?

Sign in
Breaking News

WIL Research Acquires Midwest BioResearch

WIL Research Laboratories has acquired Midwest BioResearch (MBR). The two companies will integrate their service offerings and share best practices and marketing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WIL Research Laboratories has acquired Midwest BioResearch (MBR). The two companies will integrate their service offerings and share best practices and marketing.

Midwest BioResearch has expertise in immunoanalytical and bioassay techniques and small molecule bioanalysis, supporting clinical and nonclinical research, and expertise in genetic toxicology, adding to WIL Research’s contract research service offerings including chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry and metabolism.

Michael Schlosser, Ph.D., DABT, MBR’s president and founder, will continue to lead the existing Skokie, IL site, reporting to Christopher P. Chengelis, Ph.D., DABT, WIL’s vice president and chief scientific officer.

“Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities,” said Dr. Chengelis. “We also benefit from a world-class staff with significant pharmaceutical and biotechnology industry experience and the addition of a program services consulting group.”

Sal Guccione, chief executive officer at WIL Research Holding Co., stated, “This transaction greatly enhances our capabilities to serve our clients in small and large molecule drug development. We are delighted to welcome this experienced team to the WIL family of research companies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics